Evidence map›Paper›PMID 38018014›Full record

ReviewInnate immunity2024

Immunomodulatory actions of myeloid-derived suppressor cells in the context of innate immunity.

Nikoleta Bizymi, Andreas M Matthaiou, Irene Mavroudi, Aristea Batsali, Helen A Papadaki

Abstract readReview
In one paragraph

Review in Innate immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Nikoleta BizymiDepartment of Haematology, University Hospital of Heraklion, Heraklion, Crete, Greece.ORCID 0000-0001-5199-1519
Andreas M MatthaiouLaboratory of Molecular and Cellular Pneumonology, School of Medicine, University of Crete, Heraklion, Crete, Greece.ORCID 0000-0003-1941-0213
Irene MavroudiDepartment of Haematology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Aristea BatsaliDepartment of Haematology, University Hospital of Heraklion, Heraklion, Crete, Greece.
Helen A PapadakiDepartment of Haematology, University Hospital of Heraklion, Heraklion, Crete, Greece.ORCID 0000-0002-5146-9699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloid-derived suppressor cells (MDSCs) are notable innate immune cells, which are further divided into two subpopulations, i.e., monocytic and granulocytic. These cells are traditionally considered to mainly suppress the T-cell responses. However, more updated data indicate that their properties are rather immunomodulatory than solely immunosuppressive. Indeed, MDSCs display extensive crosstalk with other either innate or adaptive immune cells, and, according to the situation under which they are triggered, they may enhance or attenuate the immune response. However, their positive role in host's defense mechanisms under specific conditions is rarely discussed in the literature. In this mini-review, the authors briefly summarise the mechanisms of action of MDSCs under distinct conditions, such as infections and malignancies, with a particular emphasis on their role as components of the innate immunity system.

Indexed as

Myeloid-Derived Suppressor CellsNeoplasmsHumansImmunity, InnateMonocytesT-Lymphocytesinfectioninnate immune cellsinnate immune responseinnate immunitymyeloid-derived suppressor cells

Identifiers

PMID38018014
PMCPMC10720601

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.